Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Global Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight 2016: One of Roche's Three Her2+ Breast Cancer Drugs, Recorded a 15% Sales Increase in the US and a 10% Rise Overall - Research and Markets

Research and Markets
Posted on: 24 Oct 16

DUBLIN, October 21, 2016 /PRNewswire/ --

Research and Markets has announced the addition of the "Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight" clinical trials to their offering.

The Herceptin (Trastuzumab) Biosimilar Clinical Trial Insight report gives comprehensive clinical insight on 37 biosimilar version of Herceptin drug in clinical pipeline. Currently there are 4 biosimilars in Phase-III trials and are expected to be commercially available in next 5-8 years. Currently 3 biosimilar version of Herceptin are commercially available in India and Iran for the treatment of Breast cancer. The patent on Herceptin expired in 2014.

Trastuzumab or Herceptin is a recombinant DNA derived humanized monoclonal antibody that interferes with the HER2/Neu receptor. It is the most common biological therapy used particularly for breast cancer, against the Her2+ receptor which stands for Human Epidermal Growth Factor Receptor 2-positive. In some cancers, notably certain types of breast cancer, HER2 is over-expressed, and causes cancer cells to reproduce uncontrollably.

Herceptin, one of Roche's three HER2+ breast cancer drugs, recorded a 15% sales increase in the US and a 10% rise overall. Sales were driven by longer duration of treatment in combination with Perjeta, another HER2+ breast cancer treatment from Roche, for both early and advanced breast cancer. China and Brazil also contributed to strong growth in Herceptin sales.

It costs around US$ 70,000 for full course treatment, thus allowing the big blockbuster for Roche with the sales of US$ 6.79 Billion in 2015; it is the drug that remained third best seller after about 15 years on the market. Roche has changed the trade name of the drug and has re-introduced an affordable version of the same in the Indian market. The new drug named Herclon would cost approximately INR  75,000 (US$ 1122) in the Indian market.

Biocon Limited, a pharmaceutical in India had received Marketing Authorization from the Drugs Controller General of India (DCGI) for its biosimilar Trastuzumab being developed jointly with Mylan, for the treatment of Her 2+ metastatic breast cancer. The regulatory approval for biosimilar Trastuzumab in India is the world's first biosimilar version under the brand name of CANMAb.

Key Topics Covered:

1. Herceptin (Trastuzumab) Clinical Insight

1.1 Clinical Introduction

1.2 Company Partnerships & Agreements

1.3 Patent Analysis by Indication

1.4 Brand Names by Country/Region

Herceptin Biosimilars Clinical Insight by Company

2. BOW 040

3. Trastuzumab Biosimilar - ISU Abxis

4. Trastuzumab Biosimilar - Allergan/Amgen

5. Trastuzumab Biosimilar - Alteogen/Cristalia

6. Trastuzumab Biosimilar - AryoGen Biopharma

7. Trastuzumab Biosimilar - Axxo

8. Trastuzumab Biosimilar - Biocad

9. Trastuzumab Biosimilar - BIOCND/Genor Biopharma

10. Trastuzumab Biosimilar - Biocon/Mylan

11. Trastuzumab Biosimilar - Bionovis/The Instituto Vital Brazil

12. Trastuzumab Biosimilar - BioXpress Therapeutics

13. Trastuzumab Biosimilar - Celltrion

14. Trastuzumab Biosimilar - Curaxys

15. Trastuzumab Biosimilar - Dong-A ST/Meiji Seika Pharma

16. Trastuzumab Biosimilar - Dr. Reddy's Laboratories

17. Trastuzumab Biosimilar - Gedeon Richter

18. Trastuzumab Biosimilar - Hanwha Biologics

19. Trastuzumab Biosimilar - Harvest Moon Pharmaceuticals

20. Trastuzumab Biosimilar - Hetero Drugs

21. Trastuzumab Biosimilar - International Biotech Center Generium

22. Trastuzumab Biosimilar - Mabion

23. Trastuzumab Biosimilar - mAbxience

24. Trastuzumab Biosimilar - Nanogen Biopharmaceutical

25. Trastuzumab Biosimilar - Nichi-Iko Pharmaceutical/Aprogen

26. Trastuzumab Biosimilar - Oncobiologics

27. Trastuzumab Biosimilar - Paras Biopharmaceuticals

28. Trastuzumab Biosimilar - Pfizer

29. Trastuzumab Biosimilar - PlantForm Corporation

30. Trastuzumab Biosimilar - Polpharma

31. Trastuzumab Biosimilar - ProBioGen AG/Bio Farma Indonesia

32. Trastuzumab Biosimilar - Reliance Life Sciences

33. Trastuzumab Biosimilar - Samsung Bioepis

34. Trastuzumab Biosimilar - Shanghai CP Guojian Pharmaceutical

35. Trastuzumab Biosimilar - Shanghai Henlius Biotech

36. Trastuzumab Biosimilar - STC Biologics

37. Trastuzumab Biosimilar - Therapeutic Proteins International

38. Trastuzumab Biosimilar - Zydus

39. Trastuzumab Glyco-optimised - Glycotope

40. Trastuzumab Subcutaneous

For more information about this clinical trials report visit http://www.researchandmarkets.com/research/lrq3xm/herceptin

About Research and Markets

Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets

Laura Wood, Senior Manager

press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470

For U.S./CAN Toll Free Call +1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907

Fax (outside U.S.): +353-1-481-1716

For more information:
www.researchandmarkets.com

Editor's Details

Mike Wood
PharmiWeb.com
www.pharmiweb.com
editor@pharmiweb.com

Last updated on: 24/10/2016

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.